Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emicizumab in mild or moderate hemophilia A without factor VIII inhibitors
NL-OMON48013Phase 3Completed
- Sponsor
- Roche
- Start
- Sep 2020
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of emicizumab in hemophilia A (3 arms), sponsored by Roche. Primary endpoints: Incidence and severity of adverse events, Incidence of thromboembolic events and 11 more. Started Sep 2020; status: completed.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NL-OMON48013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48013.